Tallam Inpatient Medicine is categorized under Proprietary (Patent) Medicines, Nec in Ballwin, MO and active since 2004.
Tallam Inpatient Medicine was established in 2004, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Proprietary (Patent) Medicines, Nec business, which does work in the B2B market, and is classified as a Proprietary (Patent) Medicines, Nec, under code number 424210 by the NAICS.
If you are seeking more information, feel free to contact Praveen Tallam at the company’s single location by writing to 1570 Buckhurst Court, Ballwin, Missouri MO 63021 or by phoning (636) 256-0690. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Tallam Inpatient Medicine |
Contact Person: | Praveen Tallam |
Address: | 1570 Buckhurst Court, Ballwin, Missouri 63021 |
Phone Number: | (636) 256-0690 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2004 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Proprietary (Patent) Medicines, Nec |
SIC Code: | 5122 |
NAICS Code: | 424210 |
Share This Business: |
Tallam Inpatient Medicine was started in 2004 to provide professional Proprietary (Patent) Medicines, Nec under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Praveen Tallam for inquiries that concern Tallam Inpatient Medicine by calling the company number (636) 256-0690, as your correspondence is most welcome. Additionally, the physical location of the single location of Tallam Inpatient Medicine can be found at the coordinates 38.574474,-90.580694 as well as the street address 1570 Buckhurst Court in Ballwin, Missouri 63021.
For its online presence, you may visit Tallam Inpatient Medicine’s website at and engage with its social media outlets through on Twitter and on Facebook.